Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways von Balasa, Balaji, Yun, Rui, Belmar, Nicole A., Fox, Melvin, Chao, Debra T., Robbins, Michael D., Starling, Gary C., Rice, Audie G.

Volltext

CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma von Hsi, Eric D, Steinle, Roxanne, Balasa, Balaji, Szmania, Susann, Draksharapu, Aparna, Shum, Benny P, Huseni, Mahrukh, Powers, David, Nanisetti, Amulya, Zhang, Yin, Rice, Audie G, van Abbema, Anne, Wong, Melanie, Liu, Gao, Zhan, Fenghuang, Dillon, Myles, Chen, Shihao, Rhodes, Susan, Fuh, Franklin, Tsurushita, Naoya, Kumar, Shankar, Vexler, Vladimir, Shaughnessy, Jr, John D, Barlogie, Bart, van Rhee, Frits, Hussein, Mohamad, Afar, Daniel E H, Williams, Marna B

Volltext

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC von Collins, Shauna M., Bakan, Courtney E., Swartzel, Gina D., Hofmeister, Craig C., Efebera, Yvonne A., Kwon, Hakju, Starling, Gary C., Ciarlariello, David, Bhaskar, Shakthi, Briercheck, Edward L., Hughes, Tiffany, Yu, Jianhua, Rice, Audie, Benson, Don M.

Volltext

Anti-CSl humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu von TAI, Yu-Tzu, DILLON, Myles, VAN ABBEMA, Anne, JESAITIS, Lynne, CARAS, Ingrid, LAW, Debbie, WELLER, Edie, WANLING XIE, RICHARDSON, Paul, MUNSHI, Nikhil C, MATHIOT, Claire, AVET-LOISEAU, Hervé, WEIHUA SONG, AFAR, Daniel E. H, ANDERSON, Kenneth C, LEIBA, Merav, LI, Xian-Feng, BURGER, Peter, LEE, Alfred I, PODAR, Klaus, HIDESHIMA, Teru, RICE, Audie G

Volltext

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma von van Rhee, Frits, Szmania, Susann M, Dillon, Myles, van Abbema, Anne M, Li, Xin, Stone, Mary K, Garg, Tarun K, Shi, JuMei, Moreno-Bost, Amberly M, Yun, Rui, Balasa, Balaji, Ganguly, Bishwa, Chao, Debra, Rice, Audie G, Zhan, Fenghuang, Shaughnessy, Jr, John D, Barlogie, Bart, Yaccoby, Shmuel, Afar, Daniel E H

Volltext

Isoelectric Focusing Technology Quantifies Protein Signaling in 25 Cells von O'Neill, Roger A., Bhamidipati, Arunashree, Bi, Xiahui, Deb-Basu, Debabrita, Cahill, Linda, Ferrante, Jason, Gentalen, Erik, Glazer, Marc, Gossett, John, Hacker, Kevin, Kirby, Celeste, Knittle, James, Loder, Robert, Mastroieni, Catherine, MacLaren, Michael, Mills, Thomas, Nguyen, Uyen, Parker, Nineveh, Rice, Audie, Roach, David, Suich, Daniel, Voehringer, David, Voss, Karl, Yang, Jade, Yang, Tom, Vander Horn, Peter B.

Volltext

Design, Synthesis, and Evaluations of Substituted 3-[(3- or 4-Carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases von Sun, Li, Tran, Ngoc, Liang, Congxin, Tang, Flora, Rice, Audie, Schreck, Randall, Waltz, Kara, Shawver, Laura K, McMahon, Gerald, Tang, Cho

Volltext

Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion von Wang, Xueyan, Le, Phuong, Liang, Congxin, Chan, Julie, Kiewlich, David, Miller, Todd, Harris, Dave, Sun, Li, Rice, Audie, Vasile, Stefan, Blake, Robert A, Howlett, Anthony R, Patel, Neela, McMahon, Gerald, Lipson, Kenneth E

Volltext

Effect of Elotuzumab on Circulating Lymphocytes, Chemokines, and Cytokines In Multiple Myeloma Patients von Neyer, Lauri, Ding, Han, Chen, Doreen, Sheridan, James P, Rice, Audie, Balasa, Balaji, Keller, Steve, Fang, Yuni, Albano, Angie, Tran, Ninian, Zhao, Vivian, Afar, Daniel EH

Volltext

SU9516: biochemical analysis of cdk inhibition and crystal structure in complex with cdk2 von Moshinsky, Deborah J, Bellamacina, Cornelia R, Boisvert, David C, Huang, Ping, Hui, Terence, Jancarik, Jaru, Kim, Sung-Hou, Rice, Audie G

Volltext

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu von Tai, Yu-Tzu, Dillon, Myles, Song, Weihua, Leiba, Merav, Li, Xian-Feng, Burger, Peter, Lee, Alfred I., Podar, Klaus, Hideshima, Teru, Rice, Audie G., van Abbema, Anne, Jesaitis, Lynne, Caras, Ingrid, Law, Debbie, Weller, Edie, Xie, Wanling, Richardson, Paul, Munshi, Nikhil C., Mathiot, Claire, Avet-Loiseau, Hervé, Afar, Daniel E.H., Anderson, Kenneth C.

Volltext

Natural killer (NK) cell activation, cytokine production, and cytotoxicity in human PBMC/myeloma cell co-culture exposed to elotuzumab (Elo) alone or in combination with lenalidomi... von Balasa, Balaji, Yun, Rui, Belmar, Nicole, Starling, Gary, Rice, Audie

Volltext

Effects of a CDK inhibitor on lens regeneration von Tsonis, Panagiotis A., Madhavan, Mayur, Call, Mindy K., Gainer, Sarah, Rice, Audie, Del Rio-Tsonis, Katia

Volltext

Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-[alpha] pathways von Balasa, Balaji, Yun, Rui, Belmar, Nicole A, Fox, Melvin, Chao, Debra T, Robbins, Michael D, Starling, Gary C, Rice, Audie G

Volltext

Asterriquinones produced by Aspergillus candidus inhibit binding of the Grb-2 adapter to phosphorylated EGF receptor tyrosine kinase von ALVI, K. A, PU, H, LUCHE, M, RICE, A, APP, H, MCMAHON, G, DARE, H, MARGOLIS, B

Volltext

Blockade of Vascular Endothelial Growth Factor Receptor I (VEGF-RI), but not VEGF-RII, Suppresses Joint Destruction in the K/BxN Model of Rheumatoid Arthritis von De Bandt, Michel, Ben Mahdi, Meriem H, Ollivier, Veronique, Grossin, Maggy, Dupuis, Magali, Gaudry, Murielle, Bohlen, Peter, Lipson, Kenneth E, Rice, Audie, Wu, Yan, Gougerot-Pocidalo, Marie-Anne, Pasquier, Catherine

Volltext

A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells von LANE, Maureen E, YU, Bo, RICE, Audie, LIPSON, Kenneth E, LIANG, Chris, LI SUN, CHO TANG, MCMAHON, Gerald, PESTELL, Richard G, WADLER, Scott

Volltext

CS-1 Is Expressed in Nasal Type NK/T Cell Lymphomas and Angioimmunoblastic T-Cell Lymphomas: Implications for Targeted Therapy with Elotuzumab (HuLuc63) von Hsi, Eric D, Steinle, Roxanne, Balasa, Balaji, Rice, Audie, Ko, Young-Hyeh, Afar, Daniel E.H.

Volltext

The oxidative mechanism of action of ortho-quinone inhibitors of protein-tyrosine phosphatase α is mediated by hydrogen peroxide von Bova, Michael P., Mattson, Matthew N., Vasile, Stefan, Tam, Danny, Holsinger, Leslie, Bremer, Meire, Hui, Terence, McMahon, Gerald, Rice, Audie, Fukuto, Jon M.

Volltext

HuLuc63 in Combination Regimens with Conventional and Targeted Therapies Has Additive and Synergistic Anti-Tumor Activity in Pre-Clinical Models of Myeloma von Rice, Audie G., Dillon, Myles B.C., Van Abbema, Anne M., Afar, Daniel E.H.

Volltext